文献速递心脑血管急症重症综合管理与镇静镇痛

未稀释左乙拉西坦快速给药的安全性与耐受性

Safety and Tolerability of Rapid Administration Undiluted Levetiracetam.
PubMed 文献 · Neurocrit Care · 2020-01-01
一句话结论回顾性研究显示,≤1000 mg 未稀释左乙拉西坦快速静脉给药耐受良好,98.5% 患者未出现不良效应。

本研究回顾性评估了2018年1月1日至2018年6月1日期间接受至少一剂未稀释左乙拉西坦且年龄≥18岁患者的药物不良反应。共纳入199例患者、1626剂左乙拉西坦,多数患者给药1000 mg(60.8%)、经外周静脉通路(64.3%)、用于癫痫预防(58.3%)。98.5%患者未发生不良效应,1.5%患者出现激越、谵妄、意识模糊和/或嗜睡,这些均为左乙拉西坦已知不良反应。作者认为≤1000 mg未稀释左乙拉西坦快速给药耐受良好,无浓度相关副作用,但需进一步前瞻性研究确认该观察结果及更高剂量的安全性。

要点

  • 199例患者共接受1626剂未稀释左乙拉西坦,98.5%患者未发生不良效应。
  • 1.5%患者出现激越、谵妄、意识模糊和/或嗜睡,均为左乙拉西坦已知不良反应。
  • 多数给药为1000 mg(60.8%)、经外周静脉通路(64.3%)、用于癫痫预防(58.3%)。
  • 患者平均接受8.1±8剂,平均治疗时长5±4.5天。
  • 作者认为≤1000 mg未稀释左乙拉西坦快速给药耐受良好,无浓度相关副作用,需进一步前瞻性研究确认。

适用人群与场景

  • 年龄≥18岁、接受至少一剂未稀释左乙拉西坦静脉给药的患者。

处置流程与药物剂量

  • 未稀释左乙拉西坦剂量≤1000 mg快速静脉给药;多数患者给药1000 mg(60.8%),经外周静脉通路(64.3%)。

研究设计与关键结果

  • 回顾性研究,纳入199例患者、1626剂左乙拉西坦,评估未稀释左乙拉西坦相关药物不良反应,安全性终点从给药时收集至出院。
  • 98.5%患者未发生不良效应,1.5%患者出现激越、谵妄、意识模糊和/或嗜睡。
  • 多数患者给药1000 mg(60.8%)、经外周静脉通路(64.3%)、用于癫痫预防(58.3%);平均接受8.1±8剂,平均治疗时长5±4.5天。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为≤1000 mg未稀释左乙拉西坦快速静脉给药耐受良好,无浓度相关副作用;需进一步前瞻性研究确认该观察结果及更高剂量的安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVE: Levetiracetam (LEV) is an antiepileptic drug used widely in patients with a favorable safety profile. Studies evaluating the safety and efficacy of intravenous (IV) LEV included volumes of at least 100 mL. Minimally diluted doses administered over 5-6 min were found to be both safe and effective. Given the complexities of admixing, this practice can be impractical and result in delays in antiepileptic therapy. This study aimed to retrospectively review the safety and tolerability of rapid administration of undiluted LEV doses ≤ 1000 mg.

METHODS: This was a retrospective study evaluating adverse drug reactions associated with undiluted LEV from January 1, 2018-June 1, 2018. Patients were included if they received at least one dose of undiluted LEV and were ≥ 18 years old. Safety endpoints were reviewed and collected from the time administration until hospital discharge. Endpoints included injection site pain and discomfort, injection site erythema, extravasation, IV line replacement, and any documented adverse effect leading to IV LEV discontinuation. Descriptive statistics were used to analyze the data.

RESULTS: A total of 199 patients were included in the study totaling 1626 doses of LEV. Most patients were administered LEV 1000 mg (60.8%), through a peripheral line (64.3%), and were prescribed LEV for seizure prophylaxis (58.3%). Patients received a mean of 8.1 ± 8 doses for a mean duration of therapy of 5 ± 4.5 days. About 98.5% of patients did not experience an adverse effect, whereas 1.5% of patients experienced agitation, delirium, confusion, and/or lethargy, which is well known to LEV therapy.

CONCLUSIONS: Rapid administration of undiluted LEV doses ≤ 1000 mg were well tolerated with no concentration-related side effects. Further prospective research is needed to confirm this observation as well as the safety of higher doses.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Morgan O, Medenwald B. Safety and Tolerability of Rapid Administration Undiluted Levetiracetam. Neurocrit Care. 2020. PMID: 30919301. doi:10.1007/s12028-019-00708-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。